Suppr超能文献

RNA干扰介导的编码孢子壁蛋白基因的敲低赋予欧洲蜜蜂抗感染保护。

RNA Interference-Mediated Knockdown of Genes Encoding Spore Wall Proteins Confers Protection against Infection in the European Honey Bee, .

作者信息

He Nan, Zhang Yi, Duan Xin Le, Li Jiang Hong, Huang Wei-Fone, Evans Jay D, DeGrandi-Hoffman Gloria, Chen Yan Ping, Huang Shao Kang

机构信息

College of Animal Sciences (Bee Science), Fujian Agriculture and Forestry University, Fuzhou 350002, China.

Guangdong Key Laboratory of Animal Conservation and Resource Utilization, Guangdong Public Laboratory of Wild Animal Conservation and Utilization, Institute of Zoology, Guangdong Academy of Sciences, Guanzhou 510260, China.

出版信息

Microorganisms. 2021 Feb 27;9(3):505. doi: 10.3390/microorganisms9030505.

Abstract

(Opisthosporidia: Microsporidia) is an emergent intracellular parasite of the European honey bee () and causes serious disease which has been associated with worldwide honey bee colony losses. The only registered treatment for disease is fumagillin-b, and this has raised concerns about resistance and off-target effects. Fumagillin-B is banned from use in honey bee colonies in many countries, particularly in Europe. As a result, there is an urgent need for new and effective therapeutic options to treat disease in honey bees. An RNA interference (RNAi)-based approach can be a potent strategy for controlling diseases in honey bees. We explored the therapeutic potential of silencing the sequences of two encoded spore wall protein (SWP) genes by means of the RNAi-based methodology. Our study revealed that the oral ingestion of dsRNAs corresponding to SWP8 and SWP12 used separately or in combination could lead to a significant reduction in spore load, improve immunity, and extend the lifespan of -infected bees. The results from the work completed here enhance our understanding of honey bee host responses to microsporidia infection and highlight that RNAi-based therapeutics are a promising treatment for honey bee diseases.

摘要

(后孢子虫纲:微孢子虫)是欧洲蜜蜂()新出现的一种细胞内寄生虫,可引发严重疾病,这种疾病与全球范围内蜜蜂蜂群数量减少有关。治疗该疾病的唯一注册药物是烟曲霉素 - b,这引发了对耐药性和脱靶效应的担忧。在许多国家,尤其是欧洲,烟曲霉素 - b被禁止用于蜜蜂蜂群。因此,迫切需要新的有效治疗方法来治疗蜜蜂的该疾病。基于RNA干扰(RNAi)的方法可能是控制蜜蜂疾病的有效策略。我们通过基于RNAi的方法探索了沉默两个编码孢子壁蛋白(SWP)基因序列的治疗潜力。我们的研究表明,单独或联合口服与SWP8和SWP12对应的双链RNA(dsRNA)可显著降低孢子载量,提高免疫力,并延长感染该寄生虫的蜜蜂的寿命。此处完成的工作结果加深了我们对蜜蜂宿主对微孢子虫感染反应的理解,并突出表明基于RNAi的疗法是治疗蜜蜂疾病的一种有前景的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b1a/7997338/be98bb73402b/microorganisms-09-00505-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验